Enrollment Completed by GCT for POAG study
Enrollment goal was reached for the Phase III study in ocular hypertension or primary open angle glaucoma managed by GCT. POAG is a serious condition in which the measured eye pressure is consistently greater than normal, which leads to optic nerve damage and vision loss.
The trial designed as a multicentre, randomised, cross-over type and is conducted in Russia. The regulatory approval was obtained in the minimal period of time, which helped to meet the Sponsor’s timelines. All patients are enrolled in the trial now, and the treatment phase will continue per protocol. GCT looks forward to facilitating the achievement of the next milestone for this study.
Updated: March 13, 2020
Permanent link: https://2022.gctrials.com/news/enrollment-completed-by-gct-for-poag-study/